INDP
Indaptus Therapeutics Inc
NASDAQ: INDP · HEALTHCARE · BIOTECHNOLOGY
$1.82
+5.20% today
Updated 2026-07-29
Market cap
$347.76M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-12.70
Dividend yield
—
52W range
$1 – $10
Volume
1.2M
WallStSmart proprietary scores
17
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.5
Quality
C+3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$10.00
+449.45%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-7.01M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-14.32M | $-15.42M | $-15.02M | $-20.85M | $-2.54M |
| EPS | — | — | — | — | $-12.70 |
| Free cash flow | $-13.25M | $-13.41M | $-12.32M | $-14.82M | $-7.01M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-23 | LAZAR, DAVID E. | Sale | 700,000 | — |
| 2026-03-23 | LAZAR, DAVID E. | Sale | 196,800 | — |
| 2026-02-26 | JABBOUR, JEROME D | Buy | 25,000 | — |
Peer comparison
Smart narrative
Indaptus Therapeutics Inc trades at $1.82. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score.
Frequently asked questions
What is Indaptus Therapeutics Inc's stock price?
Indaptus Therapeutics Inc (INDP) trades at $1.82.
Is Indaptus Therapeutics Inc overvalued?
Indaptus Therapeutics Inc carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Indaptus Therapeutics Inc (INDP)?
The 12-month analyst consensus target is $10.00, about 449.5% above the current $1.82. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-932.00%
Beta1.14
50D MA$2.61
200D MA$2.50
Shares out0.13B
Float0.00B
Short ratio—
Avg volume1.2M
Performance
1 week-1.50%
1 month-26.54%
3 months+12.88%
YTD-9.62%
1 year—
3 years—
5 years—